Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $21.29

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has received an average recommendation of "Buy" from the ten research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $21.29.

STOK has been the subject of several recent analyst reports. Leerink Partners started coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They set an "outperform" rating and a $18.00 price objective for the company. Leerink Partnrs upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a report on Friday, October 11th. Chardan Capital started coverage on Stoke Therapeutics in a research report on Friday, December 20th. They issued a "buy" rating and a $24.00 price target on the stock. HC Wainwright reissued a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 6th.

Stoke Therapeutics Trading Down 4.1 %

Stoke Therapeutics stock traded down $0.47 during mid-day trading on Monday, hitting $11.02. 525,350 shares of the company's stock were exchanged, compared to its average volume of 536,883. Stoke Therapeutics has a 1-year low of $4.09 and a 1-year high of $17.58. The stock has a 50 day moving average of $12.18 and a two-hundred day moving average of $13.17. The stock has a market cap of $583.70 million, a P/E ratio of -5.25 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, research analysts predict that Stoke Therapeutics will post -2.03 EPS for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, CEO Edward M. Md Kaye sold 6,170 shares of the company's stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $78,852.60. Following the sale, the chief executive officer now owns 68,671 shares of the company's stock, valued at $877,615.38. The trade was a 8.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the completion of the transaction, the insider now directly owns 51,277 shares of the company's stock, valued at $618,913.39. This trade represents a 16.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,849 shares of company stock worth $809,421 over the last three months. Company insiders own 11.30% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

Large investors have recently modified their holdings of the stock. Barclays PLC boosted its stake in Stoke Therapeutics by 145.3% in the 3rd quarter. Barclays PLC now owns 79,740 shares of the company's stock valued at $980,000 after buying an additional 47,239 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Stoke Therapeutics by 9.7% during the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company's stock valued at $10,705,000 after acquiring an additional 76,661 shares during the period. RTW Investments LP lifted its holdings in shares of Stoke Therapeutics by 10.1% during the third quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock valued at $57,177,000 after acquiring an additional 427,447 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Stoke Therapeutics by 1,589.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company's stock valued at $936,000 after purchasing an additional 71,647 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company's stock worth $21,248,000 after purchasing an additional 137,145 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.